JPH01299234A - Extracted component of garlic - Google Patents
Extracted component of garlicInfo
- Publication number
- JPH01299234A JPH01299234A JP63131158A JP13115888A JPH01299234A JP H01299234 A JPH01299234 A JP H01299234A JP 63131158 A JP63131158 A JP 63131158A JP 13115888 A JP13115888 A JP 13115888A JP H01299234 A JPH01299234 A JP H01299234A
- Authority
- JP
- Japan
- Prior art keywords
- reduced pressure
- under reduced
- filtrate
- water
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000004611 garlic Nutrition 0.000 title claims abstract description 10
- 244000245420 ail Species 0.000 title 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 21
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 240000002234 Allium sativum Species 0.000 claims abstract description 9
- 239000012141 concentrate Substances 0.000 claims abstract description 8
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 claims abstract description 7
- 229910001863 barium hydroxide Inorganic materials 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims abstract description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 5
- 229920002670 Fructan Polymers 0.000 claims abstract description 4
- 238000009835 boiling Methods 0.000 claims abstract description 4
- 238000010438 heat treatment Methods 0.000 claims abstract description 4
- 235000014413 iron hydroxide Nutrition 0.000 claims abstract description 4
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 claims abstract description 4
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 4
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 4
- 239000007864 aqueous solution Substances 0.000 claims abstract description 3
- 238000003756 stirring Methods 0.000 claims abstract description 3
- 239000000706 filtrate Substances 0.000 claims abstract 8
- 150000007524 organic acids Chemical class 0.000 claims abstract 3
- 235000005985 organic acids Nutrition 0.000 claims abstract 3
- 239000002994 raw material Substances 0.000 claims abstract 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract 2
- 239000006000 Garlic extract Substances 0.000 claims description 11
- 235000020706 garlic extract Nutrition 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 229940127557 pharmaceutical product Drugs 0.000 claims description 3
- ZFTFOHBYVDOAMH-XNOIKFDKSA-N (2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-2-(hydroxymethyl)oxolan-2-yl]oxymethyl]-2-(hydroxymethyl)oxolane-2,3,4-triol Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(OC[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 ZFTFOHBYVDOAMH-XNOIKFDKSA-N 0.000 claims description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 2
- 239000001569 carbon dioxide Substances 0.000 claims description 2
- -1 filter Substances 0.000 claims description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims 1
- 239000002075 main ingredient Substances 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 4
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001592 potato starch Polymers 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000009965 odorless effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000008729 scordinin Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
Landscapes
- Preparation Of Fruits And Vegetables (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【発明の詳細な説明】
産業上の利用分野
本発明は総合的なにんにく有効成分の従来の製造法の欠
点をうめるべく開発したものであり、本発明により製造
される大蒜抽出成分は医薬品として用いることができる
。DETAILED DESCRIPTION OF THE INVENTION Field of Industrial Application The present invention has been developed to overcome the drawbacks of conventional methods of producing comprehensive garlic active ingredients, and the garlic extract produced according to the present invention is used as a medicine. be able to.
従来の技術
従来大蒜の無臭物質を目的とする抽出方法にあっては酵
素失活手段の不完全による有臭化が見られ、また大蒜の
精油取得を目的とするものにあっては酵素作用度の不完
全による収率の低下、組成の偏り、精油取得後物質の薬
効の低下が見られた。Conventional technology Conventional methods for extracting odorless substances from garlic have been found to produce odor due to incomplete enzyme deactivation means, and methods for obtaining essential oil from garlic have been found to produce odorization due to incomplete enzyme deactivation methods. A decrease in the yield due to incomplete preparation, an imbalance in the composition, and a decrease in the medicinal efficacy of the substance after obtaining the essential oil were observed.
発明が解決しようとする問題点
大蒜の無臭物質取得を目的とする方法においては、酵素
失活手段として加熱法が一般的であるが温度や時間の不
適切のため、酵素の保存、一部有効成分の破壊が見られ
、また精製工程の省略ないし不適切のため、精油その他
不純物の多量残存等があり、以上の結果これらの物質に
おいては、本発明物質に比較して薬理効果が格段に劣る
ものであった。Problems to be Solved by the Invention In methods aimed at obtaining odorless substances from garlic, heating is commonly used as a means of deactivating enzymes, but due to inappropriate temperature and time, preservation of the enzymes is not effective. Destruction of components was observed, and large amounts of essential oils and other impurities remained due to the omission or inappropriateness of the refining process.As a result, these substances have significantly inferior pharmacological effects compared to the substances of the present invention. It was something.
問題点を解決するための手段
本発明の特徴は以上の諸観点より種々の研究を重ねた結
果、水中にて加熱し、むらなく酵素失活を行ったのち、
圧搾汁を得て、この物に鉄イオンの無い水酸化鉄を加え
ることによって水溶性蛋白質を除去し、中和、脱色後に
メタノールにて抽出を行う。また液の濃縮は常に６０℃
以下で減圧下に行い、スコルヂニン同族体を初めとする
各種有効成分の破壊を回避した。次に不純物の除去のた
め活性炭を用い、水溶液にて吸着を行い、メタノールに
て溶出し、続いて水酸化バリウムによってフラクタンを
極力除去した。Means for Solving the Problems The feature of the present invention is that, as a result of various studies from the above points of view, after heating in water to uniformly deactivate the enzyme,
The squeezed juice is obtained, water-soluble proteins are removed by adding iron hydroxide free of iron ions to this product, and after neutralization and decolorization, extraction is performed with methanol. Also, the liquid concentration is always at 60℃.
The following reaction was carried out under reduced pressure to avoid destruction of various active ingredients including scordinin homologs. Next, in order to remove impurities, activated carbon was used for adsorption with an aqueous solution, elution was performed with methanol, and then fructans were removed as much as possible with barium hydroxide.
本発明による大蒜抽出成分に間する急性毒性試験のＬＤ
５０値はマウスにおいて腹腔内注射で雄１４．５ｇ／ｋ
ｇ雌１７．４ｇ／ｋｇ、皮下注射で雄１９．６ｇ／ｋｇ
雌２１ 、７ ｇ／ｋｙ、、経口投与では雄雄とも５０
．０ｇ／ｋ１以上であった。またラットにおけるＬＤ５
ｏ値は腹腔内注射で雄１１．８ｇ／ｋｇ＃１４．３ｇ／
ｋｇ、皮下注射で雄２６．１ｇ／Ｊ雌２２．８ｇ／ｋｇ
、経口投与では雄雌とも４０．０ｇ／ｋｇ以上であった
。LD of acute toxicity test for garlic extract components according to the present invention
50 value is 14.5 g/k for males by intraperitoneal injection in mice.
g female 17.4 g/kg, male 19.6 g/kg by subcutaneous injection
21.7 g/ky for females, 50 g/ky for both males and females by oral administration.
．． It was 0g/k1 or more. Also, LD5 in rats
O value is 11.8 g/kg for male by intraperitoneal injection #14.3 g/
kg, subcutaneous injection male 26.1g/J female 22.8g/kg
When administered orally, it was 40.0 g/kg or more in both males and females.
以下実施例にしたがい本物質の製造法とこの物質を使用
した医薬品につき述べる。The method for producing this substance and pharmaceuticals using this substance will be described below in accordance with Examples.
実施例 １
大蒜１ｋｇをとり、沸騰水浴中で約１５分間加熱した後
圧搾する。圧搾沖釣１００１に１．５ｇの水酸化鉄を加
え、時々［１しながら室温に２日間放置し、水溶性蛋白
質を除去した後、沈降炭酸カルシウムで中和し、少量の
活性炭を加えた後５戸布を用いて加圧濾過し、はとんど
無色透明の中性液を得た。これを減圧下６０℃以下で約
３０ｇにまで濃縮し、濃縮物を適量の水に溶かし、活性
炭３０ｇを加えて吸着させた後、水１１にて洗浄し、吸
着物を６０℃でメタ、ノール約３００１にて５時間浸出
する。この浸出液を６０℃以下で約１１ｇまで濃縮し、
濃縮物を少量の水に溶かし、ｆｆｒ￥しつつ少量の水酸
化バリウム液を加えてフラクタンを除去する。５戸液は
炭酸ガス及び希硫酸にて過剰の水酸化バリウムを除去し
た後、６０℃以下で減圧濃縮し、濃厚液とする。この濃
厚液を６０℃以下で減圧乾燥した後、粉砕し、４０メツ
シユで旨別し、大蒜抽出成分約１０ｇを得た。Example 1 1 kg of garlic is taken, heated in a boiling water bath for about 15 minutes, and then squeezed. Add 1.5 g of iron hydroxide to pressed Okitsuri 1001, leave it at room temperature for 2 days while stirring occasionally, remove water-soluble proteins, neutralize with precipitated calcium carbonate, and add a small amount of activated carbon. The mixture was filtered under pressure using a cloth to obtain a mostly colorless and transparent neutral liquid. This was concentrated to about 30 g under reduced pressure at 60°C or less, the concentrate was dissolved in an appropriate amount of water, 30g of activated carbon was added and adsorbed, and the adsorbed material was heated to 60°C with methanol and alcohol. Infuse for 5 hours at approximately 3001 ml. This leachate was concentrated to about 11 g at below 60°C,
Dissolve the concentrate in a small amount of water and add a small amount of barium hydroxide solution while ffr\ to remove fructan. After removing excess barium hydroxide from the liquid with carbon dioxide gas and dilute sulfuric acid, it is concentrated under reduced pressure at 60° C. or lower to obtain a concentrated liquid. This concentrated liquid was dried under reduced pressure at 60° C. or lower, then ground and separated into 40 mesh pieces to obtain about 10 g of garlic extract.
実施例 ２
実施例１で得た大蒜抽出成分を５０ｇ（以下いずれも重
量比）及びバレイショデンブン、燐酸水素カルシウム等
の賦形剤９５０ｇを均一に湛合し、散剤１００ｇを得た
。Example 2 50 g (all weight ratios hereinafter) of the garlic extract obtained in Example 1 and 950 g of excipients such as potato starch and calcium hydrogen phosphate were uniformly mixed to obtain 100 g of powder.
実施例 ３
実施例１で得た大蒜抽出成分を３６ｋｇにバレイショデ
ンブン、燐酸水素カルシウム、乳糖等の賦形剤３５．５
ｋｇ他を加えて、均一に混合後打錠し、糖衣を施して、
錠剤１６８００錠を得た。Example 3 Add 36 kg of the garlic extract obtained in Example 1 to 35.5 kg of excipients such as potato starch, calcium hydrogen phosphate, and lactose.
kg and other ingredients, mixed uniformly, compressed into tablets, coated with sugar,
16,800 tablets were obtained.
実施例 ４
実施例１で得た大蒜抽出成分５００ｍｇを水６０１０割
合で溶解し、常法により、いわゆるドリンク剤を製造し
た。Example 4 500 mg of the garlic extract obtained in Example 1 was dissolved in 6010 parts of water to produce a so-called drink by a conventional method.
実施例 ５
実施例１で得た大蒜抽出成分２００ｆｆ１ｇをバレイシ
ョデンブン等の賦形剤と混合し、計５００ｍｇの割合と
し、常法により、いわゆるカプセル剤を製造した。Example 5 200ff1g of the garlic extract obtained in Example 1 was mixed with excipients such as potato starch to give a total of 500mg, and so-called capsules were manufactured by a conventional method.
実施例２〜５の池水発明で得た大蒜抽出成分は注射剤や
その他の剤型の各種医薬品を製造することが可能である
。The garlic extract components obtained in the Ikemizu inventions of Examples 2 to 5 can be used to produce various pharmaceuticals in the form of injections and other dosage forms.
発明の効果
以上の実施例で得られた医薬品は医療用としては疲労回
復、虚弱体質、食欲増進、神経痛、リウマチ関節炎、妊
娠中毒症、更年期疾患、乳汁不足、結咳性疾患の体力増
強、盗汗、新陳代謝異常、アレルギー疾患の諸適応があ
り、また一般用医薬品としては虚弱体質、肉体疲労、病
中病後、胃腸虚弱、食欲不振、発育期の場合の滋養強壮
の諸適応がある。以上の諸適応は本発明者の協力によっ
て、全国の医療種間等において薬理実験や臨床実験が行
われた結果証明されたものである。Effects of the invention The pharmaceutical products obtained in the above embodiments are used for medical purposes such as recovery from fatigue, weak constitution, appetite increase, neuralgia, rheumatoid arthritis, preeclampsia, menopausal diseases, milk deficiency, increasing physical strength for coughing disorders, and night sweats. , metabolic abnormalities, and allergic diseases, and as an over-the-counter drug, it is used as a nourishing tonic for weak constitutions, physical fatigue, during and after illness, gastrointestinal weakness, anorexia, and during the growth period. The above-mentioned indications have been proven through pharmacological experiments and clinical experiments carried out among medical institutions across the country with the cooperation of the present inventors.
なお本島の製造法を一部修飾せるものにて、同一の有効
成分を目標とする物質にあっては健康食品、機能性食品
等にその活用が開始されつつある。By partially modifying the manufacturing method on the main island, substances that target the same active ingredients are beginning to be used in health foods, functional foods, etc.
Claims (1)
したのち、圧搾して得た圧搾汁液に、その１〜２％の水
酸化鉄をくわえ、析出する水溶性蛋白質を除去し、ろ液
に適量の炭酸カルシウムを加えて有機酸類を除き、少量
の活性炭を加えたのちろ過し、減圧下６０℃以下で濃縮
する。これにメタノールを加えて振とう抽出し、ろ過液
を減圧下６０℃以下で濃縮し、濃縮物を水溶液とし、原
料の約３％に相当する活性炭を加えて吸着させたのち、
水洗し、吸着物を原料の約３０％に相当する６０℃のメ
タノールにて浸出する。この浸出液を６０℃以下で濃縮
し、濃縮物を水に溶かし、撹拌しつつ少量の水酸化バリ
ウム溶液を加えてフラクタンを除去する。ろ液は炭酸ガ
ス及び希硫酸にて過剰の水酸化バリウムを除去したのち
、６０℃以下で減圧濃縮する。この濃縮液を６０℃以下
で減圧乾燥することを特徴とする大蒜抽出成分。 ２ 特許請求の範囲第１項に記載の大蒜抽出成分を主成
分とした医薬品。 ３ 特許請求の範囲第１項に記載の大蒜抽出成分を配合
した医薬品。[Claims] 1. After heating garlic in boiling water for 15 to 30 minutes, 1 to 2% of iron hydroxide is added to the squeezed juice obtained by squeezing, and the precipitated water-soluble protein is extracted. After removing the organic acids, add an appropriate amount of calcium carbonate to the filtrate to remove organic acids, add a small amount of activated carbon, filter, and concentrate under reduced pressure at 60° C. or lower. Methanol was added to this and extracted by shaking, the filtrate was concentrated under reduced pressure at 60°C or less, the concentrate was made into an aqueous solution, and activated carbon corresponding to about 3% of the raw material was added to adsorb it.
After washing with water, the adsorbed material is leached with methanol at 60° C., which corresponds to about 30% of the raw material. This leachate is concentrated at 60° C. or lower, the concentrate is dissolved in water, and a small amount of barium hydroxide solution is added while stirring to remove fructans. After removing excess barium hydroxide from the filtrate with carbon dioxide gas and dilute sulfuric acid, the filtrate is concentrated under reduced pressure at 60° C. or lower. A garlic extract component characterized by drying this concentrated liquid under reduced pressure at 60°C or lower. 2. A pharmaceutical product whose main ingredient is the garlic extract described in claim 1. 3. A pharmaceutical product containing the garlic extract component as set forth in claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63131158A JP2678617B2 (en) | 1988-05-27 | 1988-05-27 | Large garlic extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63131158A JP2678617B2 (en) | 1988-05-27 | 1988-05-27 | Large garlic extract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH01299234A true JPH01299234A (en) | 1989-12-04 |
| JP2678617B2 JP2678617B2 (en) | 1997-11-17 |
Family
ID=15051355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63131158A Expired - Lifetime JP2678617B2 (en) | 1988-05-27 | 1988-05-27 | Large garlic extract |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2678617B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009108020A (en) * | 2007-10-30 | 2009-05-21 | Jo Kominato | Method for producing garlic extract component |
| JP2011254755A (en) * | 2010-06-09 | 2011-12-22 | Nippon Seiyaku Kogyo Kk | Method for producing substance containing garlic extract |
-
1988
- 1988-05-27 JP JP63131158A patent/JP2678617B2/en not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009108020A (en) * | 2007-10-30 | 2009-05-21 | Jo Kominato | Method for producing garlic extract component |
| JP2011254755A (en) * | 2010-06-09 | 2011-12-22 | Nippon Seiyaku Kogyo Kk | Method for producing substance containing garlic extract |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2678617B2 (en) | 1997-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3149142C (en) | Plant extraction method | |
| CN102070727B (en) | Extraction method of sodium heparin | |
| CN101641111A (en) | Formulations containing cynara scolymus and phaseolus vulgaris extracts which are useful in the treatment of obesity | |
| KR20000023394A (en) | Enzymatic lysate of lavor and uses thereof | |
| EP1172373B1 (en) | Method for preparing zinc-oligopeptide easily absorbable by the human body | |
| CN105754000B (en) | Hijiki polysaccharide extraction process | |
| CN111117773B (en) | Method for separating nervonic acid from garlic oil and application thereof | |
| US10434148B2 (en) | Preparation method of albumin peptide combination having the action of inhibiting the proliferation of cancer cells | |
| JP2972807B2 (en) | Anti-aging food and method for producing the same | |
| CN114272280A (en) | Extraction method of safflower oil and Xinnaoqing soft capsule | |
| JPH02154693A (en) | Novel functional peptide and utilization thereof | |
| JPH01299234A (en) | Extracted component of garlic | |
| JP2001002583A (en) | Blood sugar level increase inhibitor | |
| CN101961353B (en) | Earthworm extractive, preparation method and application thereof and earthworm extractive-containing medicinal composition | |
| JP4939781B2 (en) | Composition for preventing and / or treating hypertension containing garlic component | |
| NO742027L (en) | ||
| JP3142192B2 (en) | Blood lipid improving agent and composition containing the same | |
| JPH10306032A (en) | Potency-enhancing agent | |
| CN1451395A (en) | Use of silkworm excrement extract for treating iron-deficiency anemia | |
| CN108753440A (en) | A kind of tea oil and its preparation method and application of aglycon containing Tea Saponin and flavone aglycone | |
| RU2717537C1 (en) | Dietary supplement | |
| RU2032419C1 (en) | Hepatoprotective preparation and process for producing same | |
| WO1998000148A1 (en) | Drug preparations, containing creatine with at least one salt of calcium, magnesium, manganese or zinc | |
| JP2001103929A (en) | EXTRACT DERIVED FROM I1ex LATIFOLA THUNBERG LEAF AND METHOD OF PRODUCING THE SAME | |
| CN102552383A (en) | Compound jellyfish antihypertensive dispersible tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070801 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080801 Year of fee payment: 11 |
|
| EXPY | Cancellation because of completion of term |